ABSTRACT The interactions of proinsulin with the insulin-specific receptors were investigated in purified rat liver plasma membranes. These studies were de- (1) and the elucidation of its amino acid sequence (2) investigators have performed studies both
INTRODUCTION
Since the demonstration of proinsulin as the precursor of insulin (1) and the elucidation of its amino acid sequence (2) investigators have performed studies both Received for publication 8 June 1973 and in revised form 25 July 1974. in vivo and in vitro to decide whether proinsulin possessed intrinsic biological activity or whether it was converted to insulin or some intermediate which was, in fact, the active species. These studies have been recently reviewed (3, 4) . In the circulation, there appears to be negligible conversion of proinsulin to insulin (5) (6) (7) (8) (9) , and proinsulin degradation in the liver appears to be independent of any conversion to insulin (10, 11) . However, such processes operating at the plasma membrane of target cells were specifically not excluded by these studies.
Recently, polypeptide hormone-receptor interactions have been studied extensively (for a comprehensive review see reference 12 ). In one of these studies (13), we observed that proinsulin competed with [JI] insulin for binding to insulin receptors and that the potency of proinsulin in competing with insulin was in direct proportion to its biological potency in vitro. This strongly suggested that proinsulin indeed had intrinsic, albeit reduced, biological activity, but possible conversion on the receptor was not examined. It was also found that insulin binding to the receptor sites in liver plasma membranes was independent of the hormone degradation, though both processes were present in the same subcellular fraction (14) . Proinsulin was found to bind well to the insulin degrading enzyme(s) but was itself a much poorer substrate; i.e., it behaved as an inhibitor of insulin degradation. No significant conversion of proinsulin to insulin occurred during exposure to the liver membranes (14) .
In the present study, we have investigated directly
METHODS
Materials. Purified porcine proinsulin (lot 615-1112 B-84-C and 615-1082 B-108-C), desdipeptide proinsulin (lot 615-1112 B-32), desnonapeptide proinsulin (lot 615-1112 B-31), diarginine insulin (lot 615-1070 B-16), and monoarginine insulin (lot 615-1039 B-180-4) were generously supplied by Dr. R. E. Chance (The Lilly Research Laboratories, Indianapolis, Ind.), who has described the preparation and properties of these porcine proinsulin-like and insulin-like intermediates (3, 15) . Rat proinsulin was a generous gift of Dr. D. F. Steiner. Purified porcine "monocomponent" (16) insulin (lot MCS 970, 27.2 IU/mg) was generously supplied by Dr. J. Schlichtkrull (The Novo Research Institute, Copenhagen, Denmark). The proinsulins and porcine insulin were used for iodination as well as unlabeled standards in binding studies to the membrane receptors.
Carrier free Na'"I (I-S4) was purchased from Commissariat A l'Energie Atomique (Saclay, France). A guinea pig anti-insulin serum (17) and talc tablets (Silicosorbe, 50 mg, Dreyfus Herschtel, Paris) were used in experiments me-suring degradation (14) Iodination of proinisulin anid insulin. Proinsulin and insulin were iodinated directly with 0.7-0.8 I atoms/molecule by the use of chloramine T under conditions that yield largely monoiodo-hormone that is biologically fully active (18) . Before use in these experiments the iodinated products were chromatographed on DEAE-cellulose, as described previously (18) , except that urea was omitted because of the small quantity (microgram amounts) of polypeptide applied to the ion exchanger. The chromatographic procedure removed free iodide as well as damaged and diiodinated peptides, and excluded possible contamination of labeled proinsulin with any labeled insulin. This method also separates noniodinated hormone from I-hormone, thereby enriching slightly the specific activity of the h-or- (14) . Briefly, precipitation in 5-% trichloroacetic acid, adsorption to talc, binding to antiinsulin antibody, and ability to rebind to specific receptors in liver membranes were used to measure the degree of alteration of the ['I] proinsulin and [NI]insulin, whether recovered free in the medium or recovered from the membrane -upon dissociation of the hormone-receptor complex. These methods are not equally sensitive in measuring degradation; although each method reflects, to a certain extent, the integrity of the polypeptide, the ability to bind to fresh membranes is the most sensitive method to measure alteration of the hormone, as shown in previous studies (14) .
Biological activity was assayed by measuring the insulinstimulated conversion of [U-"C] glucose to "CO2 by isolated fat cells (21), as described previously (18) , except that the fat cell concentration was reduced to 3-5 mg/ml of incubation medium.
The polyacrylamide gel electrophoresis, performed with 20%o gels (2), is described in the legend to Fig. 10 .
RESULTS

Steady-state studies
Comparison of proinsulin and insulin in inhibiting the. [ 'In earlier studies (13) we had observed that a proinsulin preparation was 20%o as potent as insulin in binding to the insulin receptors and in stimulating glucose oxidation by isolated fat cells. Since all subsequent proinsulin preparations that we have studied have 2-5%o of the potency of insulin, we presume that the first preparation consisted of partially converted intermediate(s) (see Table I ). (Fig. 4) . This indicates the absence of proinsulin-specific receptors in the liver.
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Binding studies with proinsulin intermediates. To investigate further the interactions of proinsulin with the insulin-specific receptors in liver membranes, we studied directly the binding of proinsulin-like components that lack portions of the connecting peptide segment and that possess intermediate biological activities between proinsulin and insulin (3, 15) . Proinsulin, the desnonapeptide proinsulin, the diarginine insulin, and insulin exhibited the same order of relative potency in all of the binding systems studied (Fig. 5) (27) . They have been studied in detail (28) and reviewed elsewhere (12, 29) for the study of insulin-receptor interactions.
6 Steady-state measurements (Figs. 2, 3 (Fig. 7) . From the initial slopes of the binding curves (Fig. 7, inset) together with the concentrations of binding sites derived from steady-state studies (Fig.  6) , we approximated the association (forward) rate constants (ki) for the hormone-and the prohormonereceptor interaction (Table II trasts sharply with the great difference between the association rate constants.
As indicated in Table II , there is a good agreement between numbers derived from steady-state experiments (Figs. 2, 3 , and 6) and those obtained from time-course studies (Figs. 7 and 8 ). There is also a close correspondence for the association rate constants between the measured values (from the initial velocities of the forward reactions in Fig. 7 ) and the calculated values (from the dissociation rate constants in Fig. 8 together with the dissociation constants at steady state) (Table  II) . Again, these numbers must be regarded as approximate, at least in absolute terms, because of the complexity of the insulin- (28) taneously studied under identical quantitative conditions. Moreover, insulin degradation by the membranes (14) , another important factor of discrepancy between the respective fates of insulin and proinsulin exposed to the membrane under certain experimental conditions (14) , was minimized in the present binding studies by the use of low membrane protein concentrations (28) and was less than 15% after 60 min exposure of ['l2]insulin to membranes at 300C. Thus it is clear from both the steady-state and the time-course studies that proinsulin has a 20-30-fold lower affinity for receptor than insulin and that this is mainly accounted for by a decreased ability of proinsulin to associate with receptor since, in contrast to the association rates, the dissociation rates do not appear to differ to a very large extent. The only thing that would alter this conclusion would be if conversion of proinsulin to insulin occurred on the receptor. Properties of proinsulin recovered from the membrane receptor
To examine the possibility of proinsulin conversion at the receptor site, we studied the properties of the 'I radioactivity recovered from the membrane pellet. After ['I]proinsulin had been bound to the membranes, a high concentration (30 uM) of unlabeled proinsulin was added so that the [1"I]proinsulin was dissociated from the receptor. In all of these experiments, the proportion of radioactivity recovered from the membrane pellet agreed well with the extent of dissociation of ['"I]proinsulin from membranes as measured by the time-course experiments (Fig. 8); i.e., 70-75% was dissociated after 60 min at 30'C (see legends to Figs. 9 and 10). Radioactivity thus recovered from the membranes eluted as a single major peak in a position consistent with unmodified proinsulin when submitted to gel filtration on Sephadex G-50 (fine) (Fig. 9) . Similar results were obtained with dissociation of the proinsulin-membrane receptor complex by acid treatment of the membrane pellet.
On polyacrylamide gel electrophoresis (Fig. 10) , 'I radioactivity recovered from the membranes (gel D) was indistinguishable from control [15I]proinsulin (gel C). Further, it was completely distinct not only from (Fig. 10) . This provides direct evidence that ["I]proinsulin which is dissociated from the insulin receptor in liver plasma membranes is unconverted proinsulin.
Other properties of the ["I]proinsulin recovered from the membranes also indicate the lack of conversion. The radioactive material recovered from the membranes showed little or no enhancement of binding to anti-insulin antibody or to liver membranes (Table III) give final concentrations of 7 ,uM insulin and 9 ,ttM proinsulin. Membrane-bound radioactivity was measured at the indicated times as described in the legend to Fig. 7 . The nonspecific binding, which has been subtracted from each experimental point, was determined throughout in a simultaneous experiment where unlabeled peptide at 20 itM was added to the incubation medium at the very beginning of the experimental procedure. Each point is the mean~one-half of the range for two separate experiments; in each of the experiments determinations were done in triplicate.
hibits very little degradation when compared to insulin under similar conditions (14) . DISCUSSION The observations reported here provide evidence that proinsulin interacts with the specific insulin receptors PRO . The percent of total radioactivity recovered from Sephadex G-50 (fine) columns (0.9 X 40 cm) is indicated for each eluted fraction (0.5 ml). The columns were equilibrated in Krebs-Ringer phosphate buffer containing 10 mg/ml bovine serum albumin, pH 7.5, and were eluted with the same buffer at 40C. In both control (top) and experimental (bottom) conditions, the sample of [1inI] proinsulin that was applied to the column contained ['"I]-insulin as marker. The final volume of sample applied was 0.5 ml. Vertical arrows denote the proinsulin peak (PRO) and the insulin peak (INS). The recovery of total radioactivity applied to the columns was 85%. Experimental conditions were as described in the legend to Fig. 8 , except that membranes were collected by rapid centrifugation (13) at the end of the first incubation and washed once with cold buffer. The second step (dissociation of ['I]proinsulin from the membrane pellet) was then started immediately by resuspension of the pellet in buffer containing 30 AM unlabeled proinsulin. After 60 min at 300C, the mixture was centrifuged and a sample of the supernate was applied to the column. The supernate contained 72% of the radioactivity that was initially bound to the membrane pellet.
In the control experiment, ["I]proinsulin was incubated in buffer for 60 min at 30'C and then applied to the column.
The apparent slight increase in binding ability to fresh membranes that was observed with the recovered [HI]-proinsulin (Table III) probably reflects some "purification" of the receptor-bound polypeptide similar to that previously (14) observed with receptor-bound [l"I]insulin. The possibility that conversion of proinsulin to insulin could have been masked by rapid degradation of newly formed insulin can also be ruled out. Indeed, receptor-bound insulin is not degraded and is even protected from degradation (14) . Other data in Table  III , and 0.4% of the total radioactivity were recovered in the proinsulin, the desnonapeptide proinsulin, and the insulin areas, respectively (gel C in Fig. 10) . The mechanism by which proinsulin interacts with the insulin receptor sites appears to be a direct one in that no evidence for conversion of ["1]proinsulin to insulin was observed after proinsulin had bound to the liver plasma membranes. In previous studies (14) , we observed that proinsulin, recovered free in the medium after it had been exposed to liver membranes, showed no appearance of conversion to insulin. In the present work, [lI] proinsulin that was recovered from membranes upon dissociation of the ["I]proinsulin-receptor complex was not altered in its chromatographic pattern on polyacrylamide gel electrophoresis (Fig. 10) or on Sephadex G-50 (Fig. 9) (26) , and they readopt their original conformation after reduction and reoxidation (35) . Also of interest Is the observation that the desdipeptide and the desnonapeptide proinsulins possess a higher binding affinity ( Fig. 5 and Table I ) and a higher biological potency (Table I ; reference 36) than intact proinsulin, indicating that a free NH2-terminal glycine on the A chain is an important requirement for binding to the receptor.
However, the remaining portion of the C-peptide still alters interaction of both intermediates with the receptor since their binding affinity and their biological potency are substantially lower than that of native insulin. This is in contrast to the diarginine and the monoarginine insulins, which have binding affinities and biological potencies much closer to that of insulin ( Fig. 5 and Table I). From these observations, we can conclude that the C-peptide hinders the binding process for proinsulin and proinsulin-like molecules; however, once it is formed, the proinsulin-receptor complex appears to be nearly as stable as an insulin-receptor complex.
Our results indicate that proinsulin interacts with all of the insulin receptor sites. They do not reveal, at least in the liver plasma membrane, the presence of receptor sites that would have an affinity for proinsulin (or for proinsulin intermediates) equal to or in excess of their affinity for insulin and thus would be specific for proinsulin (or for proinsulin intermediates). The present studies cannot exclude the possibility that the C-peptide itself, and not the proinsulin molecule as a whole, may interact with a specific receptor. However, the lack of biological effect of C-peptides in homologous fat tissues (36) does not favor such possibility.
Finally, our data have direct physiological and clinical implications. It is evident that the lower uptake of proinsulin by the liver insulin receptors, as well as its much slower degradation by the liver (10, 11, 14, 37) , allows more of the secreted proinsulin to reach the peripheral circulation and may account for the longer half-life of proinsulin (38) and its prolonged activity in vivo (3, 4, 39) when compared to insulin. There are several clinical states in which the proportion and/or the properties of the circulating proinsulin component(s) de- viate from the normal pattern (40) . Studies of these components at the membrane receptor level such as those described here would represent a direct measurement of their respective affinity for the insulin receptors and should give some insight into the pathophysiology of the observed syndromes.
